---
title: Use of IMSI in Poor Responders to IVF
nct_id: NCT02358733
overall_status: TERMINATED
phase: NA
sponsor: Centro de Infertilidad y Reproducción Humana
study_type: INTERVENTIONAL
primary_condition: Female Infertility
countries: Spain
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02358733.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02358733"
ct_last_update_post_date: 2019-02-28
last_seen_at: "2026-05-12T06:42:07.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Use of IMSI in Poor Responders to IVF

**Official Title:** Use of Intra-Cytoplasmic Morphologically Selected Sperm Injection (IMSI) in Poor Responders to In Vitro Fertilization (IVF): a Prospective, Double-blind, Randomized, Controlled Trial

**NCT ID:** [NCT02358733](https://clinicaltrials.gov/study/NCT02358733)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** DIfficulties with recruitment
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** Centro de Infertilidad y Reproducción Humana
- **Conditions:** Female Infertility
- **Start Date:** 2015-02
- **Completion Date:** 2019-02-27
- **CT.gov Last Update:** 2019-02-28

## Brief Summary

This is a pilot study which aims to determine the role of IMSI in poor responders.

## Detailed Description

This is a pilot study which aims to determine the role of IMSI over ICSI in poor responders to IVF, without a background of teratozoospermia.

## Eligibility

- **Minimum age:** 37 Years
- **Maximum age:** 45 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* poor ovarian response

Exclusion Criteria:

* body mass index (BMI) ≥ 30 kg/m2
* presence of endocrinopathies (e.g., diabetes, hyperprolactinemia, hypothyroidism)
* altered karyotype or documented genetic defects in one or both partners
* history of chronic, autoimmune or metabolic diseases
* altered meiosis in testicular biopsy or altered sperm-FISH
* teratozoospermia
* participation, simultaneously or within the previous 6 months, in another clinical trial with medication
```

## Arms

- **Treatment** (EXPERIMENTAL) — Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
- **Control** (ACTIVE_COMPARATOR) — Intracytoplasmic sperm injection (ICSI)

## Interventions

- **Intra-cytoplasmic Sperm Injection** (PROCEDURE) — Selection of sperm at 400x for sperm injection
- **Intra-cytoplasmic Morphologically-selected Sperm Injection** (PROCEDURE) — Selection of sperm at 6000x for sperm injection

## Primary Outcomes

- **Clinical pregnancy rate** _(time frame: Four to six weeks after embryo transfer)_ — Percentage of patients presenting with presence of an intrauterine gestational sac with embryonic cardiac activity display, evaluated by ultrasound, per cycle initiated

## Secondary Outcomes

- **Number of embryos obtained** _(time frame: Two days after egg retrieval)_
- **Percentage of cycles with embryo transfer** _(time frame: Two days after egg retrieval)_

## Locations (1)

- Centro de Infertilidad y Reproducción Humana (CIRH), Barcelona, Spain

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.centro de infertilidad y reproducción humana (cirh)|barcelona||spain` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02358733.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02358733*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*